Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS

Inflation Bubble and the Financial. Crisis economic recession. Businessman inflating dollar sign balloon with tire pump. illustration

Venture capital

AI-fueled Isomorphic bags $2.1B, the second largest biotech round ever

Isomorphic Labs, which hasn’t yet disclosed a molecule or reached the clinic, breaks the recent trend of investors putting their money behind more mature and de-risked assets.

May 13, 2026

2 min read

Tristan Manalac

Illustration showing a person processing thoughts and turning them into output

Career Advice

Scientist as strategist: expanding the role beyond the bench

Scientists who focus only on generating data risk missing their role in shaping strategy and driving innovation.

May 13, 2026

5 min read

Manali Shah

US (UNITED STATES) VS EU (EUROPEAN UNION) - Trade war and politics conflicts concept - Concept with flags painted on cracked wall

Mergers & acquisitions

Mid-sized European drugmakers are snapping up US biotechs. Will the surge continue?

European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.

May 13, 2026

4 min read

Nick Paul Taylor

Wealth and achievement, business success, businessmen sitting on chairs of money

C-suite

Lilly, J&J CEOs top pharma’s highest paid list—again

Three pharma CEOs joined the $30 million compensation club in 2025 but Eli Lilly’s David Ricks exceeded his nearest peer by more than $4 million.

May 13, 2026

5 min read

Annalee Armstrong

FDA commissioner Marty Makary speaking on a Youtube video, wearing a dark suit and a blue tie

FDA

FDA’s Makary to resign after Secretary Kennedy signs off

FDA Commissioner Marty Makary intends to resign on Tuesday, according to several sources. This report follows a tumultuous 13-month tenure in which Makary oversaw the controversial rejections of several rare disease drugs and “predictable volatility” within the agency.

May 12, 2026

4 min read

Annalee Armstrong

A boat is driving in a circle and produces a big whirlpool

IPO

Biotech’s IPO tide is finally turning, thanks in part to the recent M&A surge

After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.

May 12, 2026

5 min read

Gabrielle Masson

Business

BMS, Hengrui build 13-asset pipeline in $15B+ onco-immune deal

Of the 13 programs that the companies will advance, four will come from Hengrui Pharma and four from Bristol Myers Squibb. The remaining five assets will be jointly discovered.

May 12, 2026

2 min read

Tristan Manalac